Published: 30 Apr 2023 | Report Code: 10248389 | Pages: 197
North America Active Pharmaceutical Ingredients (API) Market is projected to grow by 4.8% annually in the forecast period and reach $120.7 billion by 2032, driven by rising adoption of biologics in disease management, increasing regulatory approvals, patent expiration of major drugs, growing trend of outsourcing and increase in the geriatric population. Highlighted with 82 tables and 75 figures, this 197-page report “North America Active Pharmaceutical Ingredients (API) Market 2022-2032 by Molecule (Small, Large), Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America Active Pharmaceutical Ingredients (API) Market and all its sub-segments through extensively detailed classifications.
Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include the identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Five Forces
The trend and outlook of North America market is forecast in an optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America Active Pharmaceutical Ingredients (API) Market in every aspect of the classification from perspectives of Molecule, Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.
Based on Molecule, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Small Molecule APIs
• Large Molecule APIs
Based on Synthesis, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Synthetic API
o Branded Synthetic API
o Generic Synthetic API
• Biotech API
o By Type
o Monoclonal Antibodies
o Recombinant Proteins
o Vaccines
o Other Biotech APIs
o By Category
o Innovative Biologic API
o Generic Biosimilar API
o By Expression
o Mammalian Expression
o Microbial Expression
o Yeast Expression
o Insect Expression
o Other Expression Technologies
• HPAPI
o Branded HPAPI
o Generic HPAPI
Based on Manufacturing Process, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Captive Manufacturing
o Branded Captive API
o Generic Captive API
• Merchant Manufacturing
o By Drug Type
o Branded Merchant API
o Generic Merchant API
o By Drug Synthesis
o Merchant Synthetic API
o Merchant Biotech API
By Therapeutic Application, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications
By Drug Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included. The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Catalent Inc.
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents: 1.1 Industry Definition and Research Scope 9 1.1.1 Industry Definition 9 1.1.2 Research Scope 10 1.2 Research Methodology 13 1.2.1 Overview of Market Research Methodology 13 1.2.2 Market Assumption 14 1.2.3 Secondary Data 14 1.2.4 Primary Data 14 1.2.5 Data Filtration and Model Design 15 1.2.6 Market Size/Share Estimation 16 1.2.7 Research Limitations 17 1.3 Executive Summary 18 2 Market Overview and Dynamics 21 2.1 Market Size and Forecast 21 2.1.1 Impact of COVID-19 on World Economy 22 2.1.2 Impact of COVID-19 on the Market 25 2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 32 2.2 Major Growth Drivers 36 2.3 Market Restraints and Challenges 44 2.4 Emerging Opportunities and Market Trends 47 2.5 Porter’s Fiver Forces Analysis 51 3 Segmentation of North America Market by Molecule 55 3.1 Market Overview by Molecule 55 3.2 Small Molecule APIs 57 3.3 Large Molecule APIs 58 4 Segmentation of North America Market by Synthesis 59 4.1 Market Overview by Synthesis 59 4.2 Synthetic API 61 4.2.1 Branded Synthetic API 62 4.2.2 Generic Synthetic API 63 4.3 Biotech API 64 4.3.1 Biotech API by Drug Type 65 4.3.1.1 Monoclonal Antibodies 66 4.3.1.2 Recombinant Proteins 67 4.3.1.3 Vaccines 68 4.3.1.4 Other Biotech APIs 69 4.3.2 Biotech API by Category 70 4.3.2.1 Innovative Biologic API 71 4.3.2.2 Generic Biosimilar API 72 4.3.3 Biotech API by Expression Technology 73 4.3.3.1 Mammalian Expression 74 4.3.3.2 Microbial Expression 75 4.3.3.3 Yeast Expression 76 4.3.3.4 Insect Expression 77 4.3.3.5 Other Expression Technologies 78 4.4 HPAPI 79 4.4.1 Branded HPAPI 80 4.4.2 Generic HPAPI 81 5 Segmentation of North America Market by Manufacturing Process 82 5.1 Market Overview by Manufacturing Process 82 5.2 Captive Manufacturing 84 5.2.1 Branded Captive API 85 5.2.2 Generic Captive API 86 5.3 Merchant Manufacturing 87 5.3.1 Merchant Manufacturing by Drug Type 88 5.3.1.1 Branded Merchant API 89 5.3.1.2 Generic Merchant API 90 5.3.2 Merchant Manufacturing by Drug Synthesis 91 5.3.2.1 Merchant Synthetic API 92 5.3.2.2 Merchant Biotech API 93 6 Segmentation of North America Market by Therapeutic Application 94 6.1 Market Overview by Therapeutic Application 94 6.2 Infectious Diseases 96 6.3 Oncology 97 6.4 Ophthalmology 98 6.5 Cardiovascular Disorders 99 6.6 Central Nervous System 100 6.7 Pulmonary Disorders 101 6.8 Orthopedics 102 6.9 Other Applications 103 7 Segmentation of North America Market by Drug Type 104 7.1 Market Overview by Drug Type 104 7.2 Branded Prescription Drugs 106 7.3 Generic Prescription Drugs 107 7.4 OTC Drugs 108 8 North America Market 2022-2032 by Country 109 8.1 Overview of North America Market 109 8.2 U.S. 112 8.3 Canada 122 8.4 Mexico 124 9 Competitive Landscape 126 9.1 Overview of Key Vendors 126 9.2 New Product Launch, Partnership, Investment, and M&A 129 9.3 Company Profiles 130 AbbVie Inc. 130 Astrazeneca 132 Aurobindo Pharma Ltd. 137 BASF 140 Bayer AG 143 Boehringer Ingelheim 147 Catalent Inc. 152 Dr. Reddy's Laboratories 155 F. Hoffmann-La Roche 157 GlaxoSmithKline plc 160 Lonza Group 165 Lupin Limited 169 Merck & Co., Inc. 172 Mylan NV 175 Novartis International AG 178 Pfizer Inc. 181 Sanofi 186 Sun Pharmaceutical Industries Ltd. 189 Teva Pharmaceutical Industries Ltd. 192 Thermo Fisher Scientific 194 Related Reports and Products 197
List of Tables: Table 1. Snapshot of North America Active Pharmaceutical Ingredients (API) Market in Balanced Perspective, 2022-2032 19 Table 2. World Economic Outlook, 2021-2031 23 Table 3. World Economic Outlook, 2021-2023 24 Table 4. Scenarios for Economic Impact of Ukraine Crisis 33 Table 5. World Health Spending by Region, $ bn, 2013-2020 42 Table 6. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn 43 Table 7. Main Product Trends and Market Opportunities in North America Active Pharmaceutical Ingredients (API) Market 47 Table 8. North America Active Pharmaceutical Ingredients (API) Market by Molecule, 2022-2032, $ bn 55 Table 9. North America Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 59 Table 10. North America Active Pharmaceutical Ingredients (API) Market: Synthetic API by Drug Type, 2022-2032, $ bn 61 Table 11. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Drug Type, 2022-2032, $ bn 65 Table 12. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Category, 2022-2032, $ bn 70 Table 13. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Expression Technology, 2022-2032, $ bn 73 Table 14. North America Active Pharmaceutical Ingredients (API) Market: HPAPI by Drug Type, 2022-2032, $ bn 79 Table 15. North America Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 82 Table 16. North America Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing by Drug Type, 2022-2032, $ bn 84 Table 17. North America Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Type, 2022-2032, $ bn 88 Table 18. North America Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Synthesis, 2022-2032, $ bn 91 Table 19. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 94 Table 20. North America Active Pharmaceutical Ingredients (API) Market by Drug Type, 2022-2032, $ bn 104 Table 21. North America Active Pharmaceutical Ingredients (API) Market by Country, 2022-2032, $ bn 110 Table 22. U.S. Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 114 Table 23. U.S. Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 114 Table 24. U.S. Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 114 Table 25. Top 15 Countries Supplying API for Medicines Consumed in the US, 2019, ?sed on Dollar Value 116 Table 26. Canada Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 123 Table 27. Canada Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 123 Table 28. Canada Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 123 Table 29. Mexico Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 125 Table 30. Mexico Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 125 Table 31. Mexico Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 125 Table 32. AbbVie Inc.: Company Snapshot 130 Table 33. AbbVie Inc.: Business Segmentation 131 Table 34. AbbVie Inc.: Product Portfolio 131 Table 35. Astrazeneca: Company Snapshot 132 Table 36. Aurobindo Pharma Ltd.: Company Snapshot 137 Table 37. Aurobindo Pharma Ltd.: Product Portfolio 138 Table 38. BASF: Company Snapshot 140 Table 39. BASF: Business Segmentation 141 Table 40. Bayer AG: Company Snapshot 143 Table 41. Bayer AG: Business Segmentation 144 Table 42. Bayer AG: Product Portfolio 144 Table 43. Boehringer Ingelheim: Company Snapshot 147 Table 44. Boehringer Ingelheim: Product Portfolio 148 Table 45. Catalent Inc.: Company Snapshot 152 Table 46. Catalent Inc.: Business Segmentation 153 Table 47. Catalent Inc.: Product Portfolio 153 Table 48. Dr. Reddy's Laboratories: Company Snapshot 155 Table 49. Dr. Reddy's Laboratories: Business Segmentation 155 Table 50. F. Hoffmann-La Roche: Company Snapshot 157 Table 51. F. Hoffmann-La Roche: Clinical Trial Service 157 Table 52. F. Hoffmann-La Roche: Business Segmentation 158 Table 53. F. Hoffmann-La Roche: Revenue by Region 158 Table 54. GlaxoSmithKline: Company Snapshot 160 Table 55. GlaxoSmithKline: Business Segmentation 161 Table 56. GlaxoSmithKline: Product Portfolio 162 Table 57. Lonza Group: Company Snapshot 165 Table 58. Lonza Group: Business Segmentation 166 Table 59. Lonza Group: Product Portfolio 166 Table 60. Lupin Limited: Company Snapshot 169 Table 61. Lupin Limited: Business Segmentation 170 Table 62. Merck & Co., Inc.: Company Snapshot 172 Table 63. Merck & Co., Inc.: Business Segmentation 173 Table 64. Mylan NV: Company Snapshot 175 Table 65. Mylan NV: Breakdown of Revenue by Region, 2022 176 Table 66. Mylan NV: Breakdown of Revenue by Product Category, 2022 176 Table 67. Novartis International AG: Company Snapshot 178 Table 68. Novartis International AG: Business Segmentation 179 Table 69. Pfizer Inc.: Company Snapshot 181 Table 70. Pfizer Inc.: Business Segmentation 182 Table 71. Pfizer Inc.: Breakdown of Revenue by Product Category 182 Table 72. Pfizer Inc.: Breakdown of Revenue by Region 183 Table 73. Pfizer Inc.: Product Portfolio 183 Table 74. Sanofi: Company Snapshot 186 Table 75. Sanofi: Business Segmentation 187 Table 76. Sanofi: Breakdown of Revenue by Region 187 Table 77. Sun Pharmaceutical Industries Limited: Company Snapshot 189 Table 78. Teva Pharmaceutical Industries Ltd.: Company Snapshot 192 Table 79. Teva Pharmaceutical Industries Ltd.: Business Segmentation 193 Table 80. Thermo Fisher Scientific: Company Snapshot 194 Table 81. Thermo Fisher Scientific: Breakdown of Revenue by Business Segment, 2020, 5 Table 82. Thermo Fisher Scientific: Breakdown of Revenue by Region, 2020, 5
List of Figures: Figure 1. Research Method Flow Chart 13 Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16 Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032 18 Figure 4. North America Active Pharmaceutical Ingredients (API) Market, 2022-2032, $ bn 21 Figure 5. Impact of COVID-19 on Business 25 Figure 6. Primary Drivers and Impact Factors of North America Active Pharmaceutical Ingredients (API) Market 36 Figure 7. GDP per capita in the World, 1960-2022, $ thousand 39 Figure 8. Leading Causes of Death in the World, 2000 and 2019, million 40 Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 41 Figure 10. World Population 65 and Over, % of Total Population, 1950-2060 41 Figure 11. Primary Restraints and Impact Factors of North America Active Pharmaceutical Ingredients (API) Market 44 Figure 12. Investment Opportunity Analysis 48 Figure 13. Porter’s Fiver Forces Analysis of North America Active Pharmaceutical Ingredients (API) Market 51 Figure 14. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Molecule, 2022-2032, % of Revenue 56 Figure 15. North America Addressable Market Cap in 2023-2032 by Molecule, Value ($ bn) and Share (%) 56 Figure 16. North America Active Pharmaceutical Ingredients (API) Market by Molecule: Small Molecule APIs, 2022-2032, $ bn 57 Figure 17. North America Active Pharmaceutical Ingredients (API) Market by Molecule: Large Molecule APIs, 2022-2032, $ bn 58 Figure 18. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, % of Revenue 59 Figure 19. Contribution to North America 2023-2032 Cumulative Revenue by Synthesis, Value ($ bn) and Share (%) 60 Figure 20. North America Active Pharmaceutical Ingredients (API) Market by Synthesis: Synthetic API, 2022-2032, $ bn 61 Figure 21. North America Active Pharmaceutical Ingredients (API) Market by Synthetic API: Branded Synthetic API, 2022-2032, $ bn 62 Figure 22. North America Active Pharmaceutical Ingredients (API) Market by Synthetic API: Generic Synthetic API, 2022-2032, $ bn 63 Figure 23. North America Active Pharmaceutical Ingredients (API) Market by Synthesis: Biotech API, 2022-2032, $ bn 64 Figure 24. North America Biotech API Market by Drug Type: Monoclonal Antibodies, 2022-2032, $ bn 66 Figure 25. North America Biotech API Market by Drug Type: Recombinant Proteins, 2022-2032, $ bn 67 Figure 26. North America Biotech API Market by Drug Type: Vaccines, 2022-2032, $ bn 68 Figure 27. North America Biotech API Market by Drug Type: Other Biotech APIs, 2022-2032, $ bn 69 Figure 28. North America Biotech API Market by Category: Innovative Biologic API, 2022-2032, $ bn 71 Figure 29. North America Biotech API Market by Category: Generic Biosimilar API, 2022-2032, $ bn 72 Figure 30. North America Biotech API Market by Expression Technology: Mammalian Expression, 2022-2032, $ bn 74 Figure 31. North America Biotech API Market by Expression Technology: Microbial Expression, 2022-2032, $ bn 75 Figure 32. North America Biotech API Market by Expression Technology: Yeast Expression, 2022-2032, $ bn 76 Figure 33. North America Biotech API Market by Expression Technology: Insect Expression, 2022-2032, $ bn 77 Figure 34. North America Biotech API Market by Expression Technology: Other Expression Technologies, 2022-2032, $ bn 78 Figure 35. North America Active Pharmaceutical Ingredients (API) Market by Synthesis: HPAPI, 2022-2032, $ bn 79 Figure 36. North America Active Pharmaceutical Ingredients (API) Market by HPAPI: Branded HPAPI, 2022-2032, $ bn 80 Figure 37. North America Active Pharmaceutical Ingredients (API) Market by HPAPI: Generic HPAPI, 2022-2032, $ bn 81 Figure 38. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, % of Revenue 82 Figure 39. Contribution to North America 2023-2032 Cumulative Revenue by Manufacturing Process, Value ($ bn) and Share (%) 83 Figure 40. North America Active Pharmaceutical Ingredients (API) Market by Manufacturing Process: Captive Manufacturing, 2022-2032, $ bn 84 Figure 41. North America Active Pharmaceutical Ingredients (API) Market by Captive Manufacturing: Branded Captive API, 2022-2032, $ bn 85 Figure 42. North America Active Pharmaceutical Ingredients (API) Market by Captive Manufacturing: Generic Captive API, 2022-2032, $ bn 86 Figure 43. North America Active Pharmaceutical Ingredients (API) Market by Manufacturing Process: Merchant Manufacturing, 2022-2032, $ bn 87 Figure 44. North America API Merchant Manufacturing Market by Drug Type: Branded Merchant API, 2022-2032, $ bn 89 Figure 45. North America API Merchant Manufacturing Market by Drug Type: Generic Merchant API, 2022-2032, $ bn 90 Figure 46. North America API Merchant Manufacturing Market by Drug Synthesis: Merchant Synthetic API, 2022-2032, $ bn 92 Figure 47. North America API Merchant Manufacturing Market by Drug Synthesis: Merchant Biotech API, 2022-2032, $ bn 93 Figure 48. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, % of Revenue 94 Figure 49. Contribution to North America 2023-2032 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%) 95 Figure 50. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Infectious Diseases, 2022-2032, $ bn 96 Figure 51. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Oncology, 2022-2032, $ bn 97 Figure 52. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Ophthalmology, 2022-2032, $ bn 98 Figure 53. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Cardiovascular Disorders, 2022-2032, $ bn 99 Figure 54. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Central Nervous System, 2022-2032, $ bn 100 Figure 55. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Pulmonary Disorders, 2022-2032, $ bn 101 Figure 56. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Orthopedics, 2022-2032, $ bn 102 Figure 57. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Other Applications, 2022-2032, $ bn 103 Figure 58. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Drug Type, 2022-2032, % of Revenue 104 Figure 59. Contribution to North America 2023-2032 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%) 105 Figure 60. North America Active Pharmaceutical Ingredients (API) Market by Drug Type: Branded Prescription Drugs, 2022-2032, $ bn 106 Figure 61. North America Active Pharmaceutical Ingredients (API) Market by Drug Type: Generic Prescription Drugs, 2022-2032, $ bn 107 Figure 62. North America Active Pharmaceutical Ingredients (API) Market by Drug Type: OTC Drugs, 2022-2032, $ bn 108 Figure 63. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Country, 2022 and 2032, % of Revenue 110 Figure 64. Contribution to North America 2023-2032 Cumulative Revenue by Country, Value ($ bn) and Share (%) 111 Figure 65. U.S. Active Pharmaceutical Ingredients (API) Market, 2022-2032, $ bn 113 Figure 66. Manufacturing Sites of APIs for U.S. Market by Country or Region, 118 Figure 67. Number and Percentage of API Facilities for the 370 U.S. Marketed Drugs on the 2019 WHO Essential Medicines List 118 Figure 68. Number and Percentage of API Facilities for the 370 U.S. Marketed Drugs on the 2019 WHO Essential Medicines List 119 Figure 69. Canada Active Pharmaceutical Ingredients (API) Market, 2022-2032, $ bn 122 Figure 70. Active Pharmaceutical Ingredients (API) Market in Mexico, 2022-2032, $ bn 124 Figure 71. Growth Stage of North America Active Pharmaceutical Ingredients (API) Industry over the Forecast Period 126 Figure 72. AstraZeneca: Breakdown of Revenue by Therapy Area, 2022 133 Figure 73. AstraZeneca: Breakdown of Revenue by Region, 2022 133 Figure 74. Boehringer Ingelheim: Revenue by Business Segment, 2019-2022 148 Figure 75. Boehringer Ingelheim: R&D Investement, 2019-2022 149
Selected Key Players: AbbVie Inc. Astrazeneca Aurobindo Pharma Ltd. BASF Bayer AG Boehringer Ingelheim Catalent Inc. Dr. Reddy's Laboratories F. Hoffmann-La Roche GlaxoSmithKline plc Lonza Group Lupin Limited Merck & Co., Inc. Mylan NV Novartis International AG Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. Thermo Fisher Scientific (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)